围绕生物类似药问世的生物医学与市场问题。
Biomedical and Market Issues Surrounding the Advent of Biosimilars.
作者信息
Cline Abigail, Turrentine Jake E
机构信息
Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.
Division of Dermatology, Department of Medicine, Augusta University, Augusta, GA, USA.
出版信息
Dermatol Ther (Heidelb). 2016 Sep;6(3):341-5. doi: 10.1007/s13555-016-0127-4. Epub 2016 Jun 21.
Abstract
As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.
摘要
由于与生物制剂相关的专利在不久的将来即将到期，一种新型疗法即将出现，且它与生物制剂颇为相似。本评论探讨了围绕生物类似药出现的生物医学和市场问题。
相似文献
1
Biomedical and Market Issues Surrounding the Advent of Biosimilars.围绕生物类似药问世的生物医学与市场问题。
Dermatol Ther (Heidelb). 2016 Sep;6(3):341-5. doi: 10.1007/s13555-016-0127-4. Epub 2016 Jun 21.
2
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.英夫利昔单抗和抗英夫利昔单抗检测方法的标准化有助于比较临床样本中原研药和生物类似药。
Inflamm Bowel Dis. 2016 Apr;22(4):969-75. doi: 10.1097/MIB.0000000000000709.
3
Biosimilars in dermatology: The wind of change.皮肤科生物类似药：变革之风。
Exp Ther Med. 2019 Aug;18(2):911-915. doi: 10.3892/etm.2019.7505. Epub 2019 Apr 18.
4
Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.生物类似药与专利生物药之间的竞争：借鉴欧洲和日本的经验
Pharmacoeconomics. 2016 Nov;34(11):1173-1186. doi: 10.1007/s40273-016-0428-6.
5
Biosimilars in inflammatory bowel disease: ready for prime time?炎症性肠病中的生物类似药：准备好进入黄金时代了吗？
Curr Opin Gastroenterol. 2015 Jul;31(4):290-5. doi: 10.1097/MOG.0000000000000184.
6
The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.生物制品和生物类似药在美国日益重要的作用：来自美国药师协会生物制品和生物类似药利益相关者会议的观点
J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):e15-e27. doi: 10.1016/j.japh.2017.05.014. Epub 2017 Jul 6.
7
Biosimilars for the treatment of psoriasis.用于治疗银屑病的生物类似药。
Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1.
8
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.生物制剂和生物类似药为何仍然如此昂贵：尽管生物类似药取得了两项胜利，但最高法院最近的裁决并未解决竞争的根本障碍。
Drugs. 2018 Nov;78(17):1777-1781. doi: 10.1007/s40265-018-1009-0.
9
Biosimilars: are they bioequivalent?生物类似药：它们具有生物等效性吗？
Dig Dis. 2014;32 Suppl 1:82-7. doi: 10.1159/000367833. Epub 2014 Dec 17.
10
The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels.类克（Remicade®）优化定量检测在评估氟克必（Flixabi®）水平中的性能。
Therap Adv Gastroenterol. 2018 Sep 23;11:1756284818796956. doi: 10.1177/1756284818796956. eCollection 2018.
本文引用的文献
1
Generic prices take flight: the FDA is struggling to ground them.仿制药价格飙升：美国食品药品监督管理局正努力加以控制。
P T. 2014 Dec;39(12):833-45.
2
First experience with therapy of severe forms of psoriasis with biosimilar infliximab.
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):491-3. doi: 10.1111/jdv.12876. Epub 2014 Nov 21.
3
Frontiers in nonclinical drug development: biosimilars.非临床药物研发前沿：生物类似药
Vet Pathol. 2015 Mar;52(2):419-26. doi: 10.1177/0300985814547282. Epub 2014 Aug 26.
4
The economics of biosimilars.生物类似药的经济学
Am Health Drug Benefits. 2013 Sep;6(8):469-78.
5
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.一项旨在证明 CT-P13 与创新型英夫利昔单抗联合甲氨蝶呤治疗活动性类风湿关节炎患者时在疗效和安全性方面等效的随机、双盲、平行分组研究：PLANETRA 研究。
Ann Rheum Dis. 2013 Oct;72(10):1613-20. doi: 10.1136/annrheumdis-2012-203090. Epub 2013 May 16.
6
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.一项比较 CT-P13 和创新型英夫利昔单抗在强直性脊柱炎患者中的药代动力学、安全性和疗效的随机、双盲、多中心、平行组、前瞻性研究：PLANETAS 研究。
Ann Rheum Dis. 2013 Oct;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091. Epub 2013 May 16.
7
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.银屑病的生物制药和生物类似药：皮肤科医生需要了解的知识。
J Am Acad Dermatol. 2012 Feb;66(2):317-22. doi: 10.1016/j.jaad.2011.08.034.
8
Cost-effectiveness of moderate-to-severe psoriasis treatment.
Expert Opin Pharmacother. 2006 Feb;7(2):157-67. doi: 10.1517/14656566.7.2.157.
Zotero 插件